Related references
Note: Only part of the references are listed.Global chemotherapy development for gastric cancer
Kazuto Harada et al.
GASTRIC CANCER (2017)
Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer
Ruta Sahasrabudhe et al.
GASTROENTEROLOGY (2017)
Clinical application of a cancer genomic profiling assay to guide precision medicine decisions
Cheryl Eifert et al.
PERSONALIZED MEDICINE (2017)
Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer
Y. Kuboki et al.
ANNALS OF ONCOLOGY (2016)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
Kazumasa Fujitani et al.
LANCET ONCOLOGY (2016)
Kirsten Ras* oncogene: Significance of its discovery in human cancer research
Nobuo Tsuchida et al.
ONCOTARGET (2016)
Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine
Masayuki Nagahashi et al.
GENOME MEDICINE (2016)
The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond
Ciara M. Kelly et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls
Peter Horak et al.
ESMO OPEN (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Does CDKN2A loss predict palbociclib benefit?
J. Gao et al.
CURRENT ONCOLOGY (2015)
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation
Saranya Chumsri et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy
Kexin Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
A mutational signature in gastric cancer suggests therapeutic strategies
Ludmil B. Alexandrov et al.
NATURE COMMUNICATIONS (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
Ji Yun Lee et al.
SCIENTIFIC REPORTS (2015)
Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance
Qiang Zuo et al.
SCIENTIFIC REPORTS (2015)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma
Miwako Kakiuchi et al.
NATURE GENETICS (2014)
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
Kai Wang et al.
NATURE GENETICS (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Richard J. Young et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Genomic profile analysis of diffuse-type gastric cancers
Yeon-Su Lee et al.
GENOME BIOLOGY (2014)
KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas
Mohammed Tanjimur Rahman et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
M. S. N. Mohd Sharial et al.
ANNALS OF ONCOLOGY (2012)
Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly
Heng Li
BIOINFORMATICS (2012)
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
Heidi Greulich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Peter Bouwman et al.
NATURE REVIEWS CANCER (2012)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
W. Ruprecht Wiedemeyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
clValid: An R package for cluster validation
Guy Brock et al.
JOURNAL OF STATISTICAL SOFTWARE (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Share Paper
